Lodovica Zullo, Medical Oncologist, PhD Candidate at Università degli Studi di Genova shared a post on LinkedIn:
“It is indeed a little source of pride for me to see both of ‘my’ students presenting their first posters at ELCC 2026 this week.
Their work builds on years of data collection within a large multicentric EGFR collaboration, each focusing on a clinically meaningful subgroup. Valentina Favorito investigated survival after definitive CRT in locally advanced EGFR-mutant NSCLC, while Brunella Napolitano explored the clinical impact of amivantamab-related adverse events in the metastatic setting.”
Other articles about NSCLC on OncoDaily.
